Correspondence
Edited by Kiriakos Xenitidis and Colin Campbell

Salience dysregulation syndrome: a patient’s view
Jim van Os has done us a service in bringing to attention the unsatisfactory nature of the concept of schizophrenia.1 He argues that the scientific evidence for the category is weak and that the present label is highly stigmatised. He suggests that a new concept – salience dysregulation syndrome – be assessed with regard to its clinical utility and patient acceptability. (Compare with Sato.2)

The term ‘symptoms’ is understandable as a constellation of symptoms rather than just one symptom. For example, I am susceptible to schizophrenia but have never heard voices and never hallucinated. That does not mean I cannot be diagnosed as having schizophrenia but have never heard voices and never hallucinated. That does not mean I cannot be diagnosed as having schizophrenia. My problem as a patient is that the terms ‘salience’ and ‘dysregulation’ are unfamiliar medical jargon.

If an alternative concept is to replace the construct ‘schizophrenia’, it needs to be acceptable to patients; that, van Os and I agree on. It needs to be understandable, neutral in tone, and without any misleading negative associations. Salience dysregulation syndrome meets the latter two criteria, but not the first. To me and other patients with whom I have discussed van Os’s proposal, the suggested terminology is obscure.


Author’s reply: I agree that the term ‘salience’ may appear obscure at first glance but let us analyse the issue in more detail. The term ‘schizophrenia’ is stigma-inducing because it confusingly and mystifyingly refers to a disease that is characterised by a ‘split mind’ – a psychological state that the public cannot personally relate to. This is different from, for example, depression, as virtually every member of the public knows that depression is about a negative emotional state that they themselves may also experience on a daily basis, albeit to a lesser degree. Say we were to call schizophrenia ‘reality distortion syndrome’ or ‘integration dysregulation syndrome’. Although the meaning of the words would certainly be clear to the general public, the problem is that these names may paradoxically also result in stigma because the people cannot relate to a universal psychological function of ‘reality’ or ‘integration’. How long will people talk to somebody at a party who ‘cannot see reality’ or is ‘not integrated’? In other words, I do not think that it is the degree of immediate and easy recognition that is important for a new name for schizophrenia, but (a) the potential of the new name to teach the general public about the experiences we call psychotic, based on (b) a scientifically valid model and (c) an aspect of psychological experience that everybody can relate to. The reality is that this is never going to be easy and cannot be solved by an appealing name alone. Salience is about how internal or external stimuli can become attention-grabbing and how this, if it is not willed, can lead to perplexing experiences that result in a search for an explanation that we subsequently call delusions. There may be some explaining to do, but maybe not an impossible message to convey.

In conclusion, I feel it is not so much important whether or not a new name is immediately clear to everybody, but whether it has got potential to make people recognise it as relating to an aspect of psychological experience that is universal. Salience may be a vehicle to teach the general public about the experiences we call psychotic. The second issue is that it may be important to move on from criticising the term schizophrenia to systematically proposing alternatives. The reason that the cogent scientific reasoning by people such as Herman van Praag,1 Mary Boyle,2 Richard Bentall3 and Ian Brockington,4 and many others did not have an impact on DSM–IV and ICD–10 may be because an alternative was never proposed. This is why I started with an alternative, not just a criticism of the term schizophrenia.


Immigration and borderline personality disorder
The study by Pascual et al1 is interesting and shows a lot of effort by the researchers, who reviewed thousands of cases despite the limitations of research methodology. However, I wonder what prompted the authors to think that immigration could be a risk factor for borderline personality disorder?

Unlike functional illnesses such as depression and schizophrenia, which can develop at any age and can have lots of predisposing factors, personality disorders develop during the early years of childhood and adolescence with most of the personality traits well established by adulthood.

Most of the immigrant groups in this study1 are from low- and middle-income countries and it is not surprising that fewer people from this group were diagnosed with borderline personality disorder as compared with the indigenous population. We know that the prevalence of personality disorders is greater in high-income/Western countries.2

If we look at the features and diagnostic criteria for personality disorders, using either DSM–IV or ICD–10, we broadly see two main factors at the base of most of the symptoms: poor coping mechanisms and maladaptive behaviours. Factors commonly seen in Western/ high-income countries which contribute to such traits...
and learned behaviours are the breakdown of community norms\(^1\) such as lack of family cohesion, lack of a social support network, dysfunctional families and child abuse. Also, in high-income countries as people enjoy more privileges, they tend to take less responsibility for their actions and expect more and more from the state. We increasingly see more pressure on social services, rather than on parents, to account for the welfare of children.

This does not mean that borderline personality disorder is exclusive to the West, but in the social context we do see more reasons for people in the West to have such traits.

Giventhe aetiological factors that we are aware of, and the crucial age factor for borderline personality disorder, it is no surprise that immigration is not a risk factor for borderline personality disorder.

This is an interesting study that confirms what was earlier suggested by Tyrer et al\(^2\) and Baleydier et al\(^3\); however, I am not sure whether a similar study in future would be useful, given that it is unlikely that immigration can be a risk factor for developing borderline personality disorder.

I do, however, agree with the authors that future studies in younger immigrants and second generations who will be more influenced by the Western way of life are likely to be interesting and helpful, especially in terms of clinical management.

---


---

Salman A. Mushtaq, Crisis Resolution Home Treatment, Swanswell Point, Stoney Stanton Road, Coventry CV1 4FH, UK. Email: ghazalizee@hotmail.com
doi: 10.1192/bjp.194.5.467b

---

Authors’ reply: We thank Dr Mushtaq for his comments on our article.\(^1\) Although we agree with his comment that it is unlikely that immigration could be a risk factor for developing borderline personality disorder, we think that this issue is still open to debate.

First, other authors such as Paris\(^2\) have suggested that the process of migration from traditional societies to Western countries could result in the development of borderline personality disorder in individuals who did not present any symptoms in their country of origin. Paris considered that although individuals could have a biological predisposition to this disorder, such as an innate affective instability, the structure of traditional societies tends to suppress the kind of psychopathology seen in borderline personality disorder. Once these patients emigrate to Western countries, this sociocultural suppression disappears.\(^2\) In contrast, Tyrer et al\(^2\) and Baleydier et al\(^3\) observed a lower incidence of personality disorders in immigrant patients admitted to psychiatric emergency services. Likewise, in a previous study that was not centred on an immigrant population, we found that patients with borderline personality disorder were less likely to be immigrants.\(^3\) For this reason, we performed an exploratory study (i.e. without an initial hypothesis) to examine whether there really was an association between immigration and borderline personality disorder, where immigration could either be a risk factor or have a ‘protective’ effect.\(^4\) Despite the fact that, in our opinion, we observed a ‘protective’ association for immigration on the development of borderline personality disorder, our results do not invalidate Paris’s hypothesis. In Spain, immigration is a relatively new phenomenon, and the majority of patients we evaluated were adults from poorer countries who were not yet totally immersed in Western culture. It is possible that in younger immigrants (whose personality has not yet been totally consolidated) or in second-generation immigrants, a higher prevalence of borderline personality disorder could eventually be observed, as suggested by Paris.\(^5\)

Second, another important point of our study is that the immigrant sample must not be considered as a homogeneous group, since important differences exist between the subgroups of immigrants according to their geographical origin. For instance, patients from sub-Saharan Africa and Asian countries were more than seven times less likely than other immigrants to be diagnosed with borderline personality disorder. Therefore, it could be suggested that certain cultural differences in these regions, for example a greater tolerance of suffering, could be useful factors to prevent the development of this disorder. The identification and analysis of these ‘protective’ cultural factors could offer future tools to prevent the appearance of borderline personality disorder in Western societies.

We would also like to highlight that although we share Dr Mushtaq’s opinion that it is unlikely that immigration may be a risk factor for borderline personality disorder, the empirical evidence so far is not only scarce but also somewhat contradictory and with important methodological limitations. In fact, our own study presents some of these limitations. To confirm our findings, more methodologically rigorous studies would be necessary.

---

Juan C. Pascual, Department of Psychiatry, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, and CIBER-SAM, Barcelona, Spain. Email: pascual@cantpau.es; Joaquim Soler, Victor Pérez, Department of Psychiatry, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, and CIBER-SAM, Barcelona, Spain
doi: 10.1192/bjp.194.5.468

Clozapine and risk of pneumonia

Taylor et al showed that among the ‘reasons for discontinuing’ clozapine is the unfortunate outcome of death.\(^1\) Out of the 21 deaths reported, five patients died from pneumonia (~24%). Interestingly, ‘there was no evidence of neutropenia or agranulocytosis in any patients at the time of death’.\(^1\)

The relationship between clozapine and infection is indeed complex. Links between clozapine agranulocytosis, and between agranulocytosis and the increased risk of infection are well
established. Other possible indirect mechanisms of clozapine predisposition to infection, particularly aspiration pneumonia, include sialorrhoea and impairment of swallowing function with oesophageal dilatation and hypomotility. However, less is known about whether clozapine has more direct pro-inflammatory effects. It has been argued that clozapine has a direct influence on different cytokines resembling an inflammatory reaction and that infection or inflammation could induce bioactivation of clozapine into its nitrenium ion. The latter can exert a toxic reaction that induces apoptosis and gives rise to elevated cytokine levels. However, these arguments are still awaiting robust research assessment.

Regardless of the cause of infection, a number of reports showed that infection leads to a rise of toxic levels in serum clozapine and its metabolites. This is likely to be mediated by cytokine suppression of cytochrome P450 1A2 (CYP1A2), the main hepatic microsomal system involved in clozapine metabolism; CYP1A2 is also involved in the metabolism of a number of antibiotics in common use for treating infections. This enhances further potentials for clozapine toxicity.

We wholeheartedly agree with Taylor et al that any bronchial infection (or indeed other infections, including wound infection) should attract immediate attention. Clinicians should bear in mind that both the infection and the drug treatment of the infection (through drug–drug interactions at CYP1A2) can lead to very high and toxic levels of serum clozapine that may lead to more adversities. In such circumstances we recommend monitoring for signs of clozapine intoxication (e.g. speech dysfluency, myoclonus and increased sedation), obtaining clozapine levels, considering significant clozapine dose reduction and working closely with physical health physicians in deciding about the most appropriate antimicrobial therapy and required supportive measures.

Authors’ reply: We thank Patricia Hogan for her comments challenging current definitions of intellectual disability and highlighting the difficulty of accurate assessment of psychotic illness in individuals with intellectual disability. With respect to the former, we note the importance of applying standard definitions and nomenclature in the study of the epidemiology of dual diagnosis. The criteria used to define intellectual disability affect prevalence rates and the use of IQ criteria alone rather than the dual criteria of IQ and adaptive behaviours will have a marked impact on rates. We employed the American Association on Mental Retardation dual criteria in our study. The use of dual criteria is the most common approach across services and in research, and is consistent with DSM–IV and ICD–10 definitions. As the American Association on Mental Retardation criteria are the basis of service eligibility in Western Australia, their use ensures a thorough assessment of individuals on the intellectual disability register and greater confidence that cases have been

dual diagnosis quandries

Morgan et al have made a useful contribution in the area of intellectual disability/mental illness dual diagnosis. However, this study, like most in this area, is flawed by inadequate definition of terms. ‘Intellectual disability’, the current phrase of fashion for this population, is unsatisfactory because many individuals in the higher IQ ranges are not disabled. The American Association on Mental Retardation (now AAIDD) definition, probably the most widely used definition, is cited. It gets around the disability issue by requiring that individuals with intellectual disability must also have ‘limitations in adaptive behaviours and skills’. This confounds the intellectual disability and mental illness categories, as such limitations may well be due to mental illness. Perhaps a better term for studies to use would be ‘intellectual impairment’, which, like visual impairment, does not necessarily imply disability; then, all individuals in certain IQ ranges could be included. As it is, a certain proportion of individuals without mental illness are excluded by the definition. This may inflate the prevalence rates.

Additionally, there is a problem in lumping together all ranges of intellectual disability. As Morgan et al note, mental illness, particularly schizophrenia, is more likely to be diagnosed in the borderline group and pervasive developmental disorder is more likely to be diagnosed in the severe/profound group. Rather than a true reflection of incidence, this may reflect a nosological bias. A strict definition of schizophrenia is difficult to apply to a non-verbal person. Historically, pervasive developmental disorder and schizophrenia have sometimes been used interchangeably in apparently disturbed and non-verbal individuals; however, since the 1990s, at least in the USA, there has been a massive shift towards the diagnosis of pervasive developmental disorder sub-categories such as autism and Asperger syndrome. The diagnosis of schizophrenia has an additional stigma which some families find unacceptable. The authors found some trends distinguishing individuals with dual diagnosis from those with intellectual disability alone. Some of these trends also distinguished borderline from other levels of intellectual disability (e.g. fewer genetic causes, less Down syndrome, less epilepsy). To distinguish dual diagnosis from intellectual disability alone, results should probably be controlled for IQ level.

Morgan et al have considered patients with dual diagnosis to have more severe mental illness than other patients with mental illness as indicated by number of hospitalisations, length of hospitalisations, etc. Perhaps this just indicates that treatment and placement options for these patients are poorer. Future studies need to be done to clarify the unique aspects of this population.


Patricia E. Hogan, Family Guidance Center, St. Joseph, MO, USA. Email: drpahogan@hotmail.com
doi: 10.1192/bjp.194.5.469

Authors’ reply: We thank Patricia Hogan for her comments challenging current definitions of intellectual disability and highlighting the difficulty of accurate assessment of psychotic illness in individuals with intellectual disability. With respect to the former, we note the importance of applying standard definitions and nomenclature in the study of the epidemiology of dual diagnosis. The criteria used to define intellectual disability affect prevalence rates and the use of IQ criteria alone rather than the dual criteria of IQ and adaptive behaviours will have a marked impact on rates. We employed the American Association on Mental Retardation dual criteria in our study. The use of dual criteria is the most common approach across services and in research, and is consistent with DSM–IV and ICD–10 definitions. As the American Association on Mental Retardation criteria are the basis of service eligibility in Western Australia, their use ensures a thorough assessment of individuals on the intellectual disability register and greater confidence that cases have been
correctly classified in this study. Although the difficulty of diagnosing psychosis accurately in individuals with intellectual disability is well documented,2,3 our paper highlights another pressing issue. The poor recognition of dual diagnosis in affected individuals as a result of the administrative separation between intellectual disability and mental health services has led to a serious underestimate of the prevalence of dual diagnosis and has created structural impediments to inter-agency approaches to integrated, person-oriented clinical practice. Critical improvements are needed both in the structure of service provision and in clinical education programmes to ensure dual diagnosis is correctly identified and appropriately treated.4,5 Otherwise dual diagnosis will continue to be recognised and treated ineffectively or, at worst, missed altogether, with important implications for best practice.


Vera A. Morgan, School of Psychiatry and Clinical Neurosciences, University of Western Australia, Perth, Australia 6000. Email: vmorgan@cyllene.uwa.edu.au; Assen A. Jablensky, School of Psychiatry and Clinical Neurosciences, University of Western Australia, Perth, Australia

doi: 10.1192/bjp.194.5.469

Correction

Suicide rates in people of South Asian origin in England and Wales: 1993–2003. BJP, 193, 406–409. Tables 1 and 2, p. 407: the second and fourth column of each table should be headed ‘England & Wales’; the third and fifth column of each table should be headed ‘South Asian’. The online article has been corrected post-publication, in deviation from print and in accordance with this correction.

doi: 10.1192/bjp.194.5.470
Immigration and borderline personality disorder
Salman A. Mushtaq
Access the most recent version at DOI: 10.1192/bjp.194.5.467b

References
This article cites 4 articles, 1 of which you can access for free at:
http://bjp.rcpsych.org/content/194/5/467.3#BIBL

Reprints/permissions
To obtain reprints or permission to reproduce material from this paper, please write to permissions@rcpsych.ac.uk

You can respond to this article at
/letters/submit/bjprcpsych;194/5/467-b

Downloaded from
http://bjp.rcpsych.org/ on April 19, 2017
Published by The Royal College of Psychiatrists

To subscribe to The British Journal of Psychiatry go to:
http://bjp.rcpsych.org/site/subscriptions/